- Home
- CHKP vs BBIO Comparison
CHKP vs BBIO Comparison
Compare CHKP & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHKP | BBIO |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 15.3B |
| IPO Year | 1997 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CHKP | BBIO |
|---|---|---|
| Price | $135.69 | $74.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 25 |
| Target Price | ★ $207.25 | $86.04 |
| AVG Volume (30 Days) | 735.7K | ★ 1.5M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $8.28 | $88.16 |
| Revenue Next Year | $6.03 | $74.13 |
| P/E Ratio | $17.05 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $135.82 | $31.77 |
| 52 Week High | $233.78 | $84.94 |
Technical Indicators
Market Signals| Indicator | CHKP | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 29.92 | 57.26 |
| Support Level | N/A | $70.65 |
| Resistance Level | $208.46 | $78.20 |
| Average True Range (ATR) | 4.87 | 2.54 |
| MACD | 0.07 | 0.48 |
| Stochastic Oscillator | 6.35 | 81.78 |
Price Performance
Historical ComparisonAbout CHKP Check Point Software Technologies Ltd.
Check Point Software Technologies is a pure-play cybersecurity vendor. The company offers solutions for network, endpoint, cloud, and mobile security in addition to security management. Check Point, a software specialist, sells to enterprises, businesses, and consumers. Around 50% of revenue is generated in Europe, the Middle East, and Africa, 40% from the Americas, and 10% from the Asia-Pacific region. The firm, based in Tel Aviv, Israel, was founded in 1993 and has about 5,000 employees.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.